-
Ресурс РМЭБ
Единая база данных, объединяющая электронные ресурсы вузов Казахстана
Подробнее -
-
Механизмы действия, преимущества и недостатки некоторых современных адъювантов
УДК:
615.371:615.012/.014
Автор статьи:
Кожанова С.В.
Соавторы:
Бижигитова Б.Б., Шортанбаев А.А.
Место работы автора:
Казахский национальный медицинский университет им. С. Асфендиярова
Название журнала:
Гигиена, эпидемиология и иммунобиология
Год выпуска:
2010
Номер журнала:
2(44)
Страницы:
с.145-149
Ключевые слова:
адъюванты, вакцины, толл-подобные рецепторы, побочные действия адъювантов, иммунный ответ.
Резюме на казахском языке:
Адъюванттардың иммунды жүйеге әсер механизмі қарастырылған, туа біткен және адаптивті иммунитет компоненттері арасындағы байланыс көрсетілген. Қазіргі адъюванттардың механизмдері, артықшылықтары мен кемшіліктері бейнеленген.
Резюме на английском языке:
Mechanism action of adjuvants on immune system were considered. Connection between components of innate and adaptive immunity was showed. Mechanism of actions, advantages and lacks of same modern adjuvants were described.
Список литературы:
1. Garson N., Goldman M. Boosting vaccine power. Sci. American. 2009, 10: 52-59.
2. Kindt T. J., Goldsby R. A., Osborne B. A. CubyImmunology, N. Y. 2007: 475-492.
3. Scheibner V. Adverse effects of adjuvants in vaccines. Nexus, V. 8, №1, 2, 2001.
4. D. I. Watkins. The vaccine search goes on. Sci. Amer., 2008, 11: 47-53.
5. Fanci A. S. et al. HIV Vaccine Research: The WayForward. Science, 2008, 321: 530-532.
6. Menegon T. et al. Influenza vaccines: antibodyresponse to split virus and MF59 adjuvanted subunitvirus in an adult population. Eur. J. Epidemiol. 1999, 15: 573-576.
7. Stoute J. A. et al. A preliminary evaluation of arecombinant protein vaccine against Plasmodium falciparummalaria. N. Engl. J. Med. 1997, 336: 86-91.
8. L. J. O'Neill. Immunity's Early-Warning System. Sci. Am. 2005, 1: 17-24.
9. Garson N., et al. Development of RTS, S/ASO2: apurified subunit-based malaria vaccine candidate formulatedwith a novel adjuvant. Expert Rev., Vaccines. 2003, 2: 231-238.
10. Levie K. et al. A dose regimen of a recombinanthepatitis B vaccine with the immune stimulant ASO4 …Scand. J. Infect. Dis. 2002, 34: 610-614.
11. McLaughlin et al. Regression of tumors in guineapigs after treatment with synthetic muramyl dipeptides. Science, 1980, 208: 415.
12. Hemmi H. et al. A Toll-like receptor recognizesbacterial DNA. Nature. 2000, 408: 708-745.
13. Hartman G. et al. Delineation of a CpG for activatingprimate immune response in vitro in vivo. J. Immunol., 2004, 164: 1617-1624.
14. Krieg A. M. et al. Induction of systemic TH1-likeinnate immunity in normal volunteers following administrationof CpG 7909 – TLR9 agonist. J. Immunother. 2004, 27: 460-471.
15. Cooper C. H. et al. CpG 7909, an ImmunostimulatoryTLR9 agonist as adjuvant to Engerix-B HBV vaccine. J. Clin. Immunol. 2004, 24: 693-701.
16. Appay V. et al. New generation vaccine induceseffective melanoma-specific CD8+ T cells. J. Immunol. 2006 177: 1670-1678.
17. Takeda K., Akira S. Toll-like receptors in innateimmunity. Int. Immunol. 2005, 17: 1-14.
18. Prinz M. Innate immunity mediated by TLR9modulate pathogenicity in an animal model of multiplesclerosis. J. Clin. Invest. 2006, 116: 456-464.
19. Ichikawa H. T. et al. Activation of APCs thoughCD40 or TLR9 overcome tolerance and precipitates autoimmunedisease. J. Immunol. 2002, 169: 2781-2787.
20. Kensil C. R. Saponins as vaccine adjuvants. Crit. Rev. Ther. Drug Carrier Syst. 1996, 13: 1-55.
21. Baugham A. D. et al. Action of saponin on biologicalcell membranes. Nature. 1962, 196: 952-955.
22. Mbawuike J. et al. Humoral and cell-mediated immuneresponses of humans to vaccines with and withoutQS-21 adjuvant. Vaccine, 2007, 25: 3263-3269.
23. Rook G. A. New meanings for an old world: adjuvanticity, cytokines and T-cells. Immunol. Today, 1993, 14: 95-96.
24. Chapman P. B. et al. Induction of antibodies byimmunizing melanoma patients using GM2 keyholelimpet hemocyanin+QS-21 vaccine. Clin. Cancer Res. 2000, 6: 874-879.
25. Ахматова Н. Х. и др. Дендритные клетки какисточник вакцин в экспериментальной и клиническойпрактике. Вопр. гематологии, онкологии и иммуно-патол. в педиатрии 2006, 5: 35-41.
26. Klinman D. M. Adjuvant properties of Oligonucleotides. R. O. Weeratna. Enhancing vaccine Immunogenicitythrough use of TLR9 agonists. In: NovelVaccines-Adjuvants & Delivery Systems, Matherials ofConference, Aug. 16, 2009.
1. Garson N., Goldman M. Boosting vaccine power. Sci. American. 2009, 10: 52-59.
2. Kindt T. J., Goldsby R. A., Osborne B. A. CubyImmunology, N. Y. 2007: 475-492.
3. Scheibner V. Adverse effects of adjuvants in vaccines. Nexus, V. 8, №1, 2, 2001.
4. D. I. Watkins. The vaccine search goes on. Sci. Amer., 2008, 11: 47-53.
5. Fanci A. S. et al. HIV Vaccine Research: The WayForward. Science, 2008, 321: 530-532.
6. Menegon T. et al. Influenza vaccines: antibodyresponse to split virus and MF59 adjuvanted subunitvirus in an adult population. Eur. J. Epidemiol. 1999, 15: 573-576.
7. Stoute J. A. et al. A preliminary evaluation of arecombinant protein vaccine against Plasmodium falciparummalaria. N. Engl. J. Med. 1997, 336: 86-91.
8. L. J. O'Neill. Immunity's Early-Warning System. Sci. Am. 2005, 1: 17-24.
9. Garson N., et al. Development of RTS, S/ASO2: apurified subunit-based malaria vaccine candidate formulatedwith a novel adjuvant. Expert Rev., Vaccines. 2003, 2: 231-238.
10. Levie K. et al. A dose regimen of a recombinanthepatitis B vaccine with the immune stimulant ASO4 …Scand. J. Infect. Dis. 2002, 34: 610-614.
11. McLaughlin et al. Regression of tumors in guineapigs after treatment with synthetic muramyl dipeptides. Science, 1980, 208: 415.
12. Hemmi H. et al. A Toll-like receptor recognizesbacterial DNA. Nature. 2000, 408: 708-745.
13. Hartman G. et al. Delineation of a CpG for activatingprimate immune response in vitro in vivo. J. Immunol., 2004, 164: 1617-1624.
14. Krieg A. M. et al. Induction of systemic TH1-likeinnate immunity in normal volunteers following administrationof CpG 7909 – TLR9 agonist. J. Immunother. 2004, 27: 460-471.
15. Cooper C. H. et al. CpG 7909, an ImmunostimulatoryTLR9 agonist as adjuvant to Engerix-B HBV vaccine. J. Clin. Immunol. 2004, 24: 693-701.
16. Appay V. et al. New generation vaccine induceseffective melanoma-specific CD8+ T cells. J. Immunol. 2006 177: 1670-1678.
17. Takeda K., Akira S. Toll-like receptors in innateimmunity. Int. Immunol. 2005, 17: 1-14.
18. Prinz M. Innate immunity mediated by TLR9modulate pathogenicity in an animal model of multiplesclerosis. J. Clin. Invest. 2006, 116: 456-464.
19. Ichikawa H. T. et al. Activation of APCs thoughCD40 or TLR9 overcome tolerance and precipitates autoimmunedisease. J. Immunol. 2002, 169: 2781-2787.
20. Kensil C. R. Saponins as vaccine adjuvants. Crit. Rev. Ther. Drug Carrier Syst. 1996, 13: 1-55.
21. Baugham A. D. et al. Action of saponin on biologicalcell membranes. Nature. 1962, 196: 952-955.
22. Mbawuike J. et al. Humoral and cell-mediated immuneresponses of humans to vaccines with and withoutQS-21 adjuvant. Vaccine, 2007, 25: 3263-3269.
23. Rook G. A. New meanings for an old world: adjuvanticity, cytokines and T-cells. Immunol. Today, 1993, 14: 95-96.
24. Chapman P. B. et al. Induction of antibodies byimmunizing melanoma patients using GM2 keyholelimpet hemocyanin+QS-21 vaccine. Clin. Cancer Res. 2000, 6: 874-879.
25. Ахматова Н. Х. и др. Дендритные клетки какисточник вакцин в экспериментальной и клиническойпрактике. Вопр. гематологии, онкологии и иммуно-патол. в педиатрии 2006, 5: 35-41.
26. Klinman D. M. Adjuvant properties of Oligonucleotides. R. O. Weeratna. Enhancing vaccine Immunogenicitythrough use of TLR9 agonists. In: NovelVaccines-Adjuvants & Delivery Systems, Matherials ofConference, Aug. 16, 2009.
Электронный вариант:
скачать
Рассмотрены механизмы действия адъювантов на иммунную систему, показана связь между компонентами врожденного и адаптивного иммунитета. Описаны механизмы действия, преимущества и недостатки некоторых современных адъювантов.
Последние Новости
- 28.11.2012
Казахстанская общенациональная пробная подписка на IEEE/IET
- 20.12.2011
В шаге от цели «Smart»
- 20.12.2011
Инновационный прорыв региона